As homophobic discrimination continues to sweep across the African continent, we should be acutely mindful of the diverse ways it harms societies. While we are most aware of the direct effect of homophobic physical violence on sexual minority groups, it is also crucial that we are cognisant of the other insidious and multifaceted ways in which stigma and discrimination impact not just on sexual minorities but also on society at large.
Data presented today at the International AIDS Conference in Melbourne and published simultaneously in the Lancet provides the first clear evidence for who wants PrEP—and how they use it outside of the United States.
No one who took Truvada PrEP at least four times per week acquired HIV in the iPrEx Open Label Extension (iPrEx OLE) demonstration project, according to data presented today at the AIDS 2014 conference in Melbourne. These new data support PrEP as a valuable HIV prevention option even when adherence may be less than 100%.
“Adherence has to be good, not great,” said iPrEx protocol chair Robert Grant, MD, MPH, of the Gladstone Institutes, the University of California at San Francisco, and San Francisco AIDS Foundation, in his late-breaker presentation of the study results.
The technique addresses the problem of hidden reservoirs of HIV in the body, and could herald a new way of battling the viral infection
AIDS researchers and policymakers from around the globe are gathering in Melbourne, Australia, for a major international conference that starts this Monday. They’ll be mourning dozens of colleagues who died in the crash of Malaysia Airlines Flight 17.
But the work of the conference will continue, and one of the major topics to be discussed is expanding the use of a pill that prevents HIV.
A new study of German gay men finds that those who discuss HIV before sex are much less likely to acquire the virus and also finds that HIV has a tendency to transmit during the first six months of a relationship, aidsmap reports. Publishing their findings in BMC Public Health, researchers studied 105 gay men with recently diagnosed HIV and compared them with 105 HIV-negative controls, collecting the data between 2008 and 2010.
A condom that can kill the HIV virus and designed by a bio-tech firm in Australia is set to hit stores within the next few months.